Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Down 13.2% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 576,400 shares, a decline of 13.2% from the January 15th total of 664,400 shares. Currently, 21.8% of the shares of the company are sold short. Based on an average trading volume of 462,000 shares, the days-to-cover ratio is currently 1.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Adage Capital Partners GP L.L.C. grew its stake in shares of Aligos Therapeutics by 48.5% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 325,000 shares of the company’s stock worth $12,948,000 after purchasing an additional 106,187 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Aligos Therapeutics in the fourth quarter worth $2,751,000. Avantax Advisory Services Inc. bought a new position in shares of Aligos Therapeutics in the fourth quarter worth $1,218,000. Drive Wealth Management LLC bought a new position in shares of Aligos Therapeutics in the fourth quarter worth $916,000. Finally, Wells Fargo & Company MN bought a new position in shares of Aligos Therapeutics in the fourth quarter worth $869,000. 60.43% of the stock is currently owned by institutional investors.

Aligos Therapeutics Price Performance

Shares of ALGS opened at $23.67 on Tuesday. The company has a market cap of $84.98 million, a P/E ratio of -1.78 and a beta of 2.45. The stock has a fifty day moving average price of $32.79 and a 200 day moving average price of $20.10. Aligos Therapeutics has a 12 month low of $6.76 and a 12 month high of $46.80.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).